Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=2&sort=-program_officials
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-program_officials", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=-program_officials", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=3&sort=-program_officials", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-program_officials" }, "data": [ { "type": "Grant", "id": "15963", "attributes": { "award_id": "1R01AG083894-01A1", "title": "Longitudinal MRI Measures of Cerebrovascular Injury and AD Atrophy in a Study of Latinos (SOL-INCA-MRI Long)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 44413, "first_name": "MARYAM X", "last_name": "GHALEH", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-03-15", "end_date": "2030-11-30", "award_amount": 3517625, "principal_investigator": { "id": 44414, "first_name": "Charles", "last_name": "DeCarli", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 44415, "first_name": "Hector M", "last_name": "Gonzalez", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 3418, "ror": "", "name": "UNIVERSITY OF CALIFORNIA AT DAVIS", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Latinos constitute a heterogeneous population which accounted for slightly more than 50% of the United States (US) population growth for 2010 to 2020. Latinos are also becoming a larger proportion of older individuals in the US. Despite this, biomarker studies of normal aging and cognitive impairment remain limited, and the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) constitutes the only known representative sample. Moreover, epidemiological data indicate that Latinos have a higher prevalence of vascular risk factors, lower cardiovascular health metrics, and a greater likelihood of having mild cognitive impairment (MCI) or dementia due non-Alzheimer’s disease processes that differ by heritage. Consequently, diagnosis and treatment of Latino persons with cognitive impairment may be more challenging, but more amenable to prevention through reduction of vascular risk factors than non-Hispanic White persons where vascular risk and disease is less prevalent. The first cycle of “MRI Measures of Cerebrovascular Injury and Alzheimer’s disease Atrophy in a Study of Latinos (RF1 AG054548; AKA SOL-INCA-MRI)” was designed to identify biological underpinnings of normal cognitive aging, MCI and Alzheimer’s disease and related dementias (ADRD) in a representative subgroup of the HCHS/SOL 62 + 9 years of age on average. Despite restrictions imposed by the COVID pandemic, our investigators successfully obtained brain MRI from 2668 individuals or >95% of the proposed study cohort. From these data we have published on 1) differences in brain structure from ages 35-85; 2) the impact of vascular risk and sleep on brain structure; 4) the association of cognition with subsequent MRI measures; and 4) genetic influences on select brain measures. These early results, while of scientific value, are cross- sectional and do not reflect ongoing degeneration or incident vascular injury, limiting inferential power that might extend scientific knowledge of brain aging and ADRD in this unique cohort. For this application, we propose to extend our work to include longitudinal MRI analysis, leveraging longitudinal biomarker and clinical data from 3 visits, spanning approximately 12 years of HCHS/SOL and its cognitive ancillary study (SOL-INCA- AD; R01 AG075758, Gonzalez, DeCarli Co-PIs) on a deeply characterized and diverse Hispanic/Latino cohort. Adding longitudinal image analysis in combination with longitudinal lifestyle, medical risk factors, plasma ATN biomarkers, genetics and cognitive assessment in this Latino cohort will address multiple ADRD research milestones and priorities while enabling stronger statistical inference of risk and resilience factors amongst representative, yet relatively young-old members of diverse Latino communities, creating the opportunity to identify modifiable risk factors, potentially reducing societal burden due to later-life ADRD in this rapidly growing portion of the older US population.", "keywords": [ "9 year old", "Age", "Aging", "Alzheimer's Disease", "Alzheimer's disease related dementia", "Amyloid beta-Protein", "Ancillary Study", "Atrophic", "Biological", "Biological Markers", "Blood Vessels", "Brain", "Brain Injuries", "COVID-19 pandemic", "Cerebrovascular Trauma", "Clinical Data", "Cognition", "Cognitive", "Cognitive aging", "Communities", "Data", "Dementia", "Diagnosis", "Disease", "Funding", "Genetic", "Genetic Risk", "Growth", "Hemorrhage", "High Prevalence", "Hispanic", "Hispanic Community Health Study/Study of Latinos", "Image Analysis", "Impaired cognition", "Individual", "Infarction", "Intercept", "K-Series Research Career Programs", "Knowledge", "Latino", "Latino Population", "Life", "Life Style", "Magnetic Resonance Imaging", "Measures", "Mediating", "Medical", "Nerve Degeneration", "Not Hispanic or Latino", "Older Population", "Participant", "Pathologic", "Persons", "Plasma", "Population", "Population Growth", "Population Heterogeneity", "Prevention", "Process", "Publishing", "Research", "Research Personnel", "Risk", "Risk Factors", "Sampling", "Sleep", "Structure", "Study of Latinos", "Subgroup", "Time", "United States", "United States National Institutes of Health", "Vascular Diseases", "Visit", "Water", "White Matter Hyperintensity", "Work", "aging brain", "brain magnetic resonance imaging", "cardiovascular health", "cerebral microbleeds", "cognitive performance", "cognitive testing", "cohort", "cohort research", "design", "disparity reduction", "endophenotype", "epidemiologic data", "gray matter", "magnetic resonance imaging biomarker", "member", "mild cognitive impairment", "modifiable risk", "morphometry", "normal aging", "resilience factor", "serial imaging", "social culture", "sociocultural determinant", "tau-1", "vascular injury", "vascular risk factor", "white matter" ], "approved": true } }, { "type": "Grant", "id": "15962", "attributes": { "award_id": "1R35GM162151-01", "title": "Correlated factor models for exploratory analysis of complex multimodal study designs", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 44411, "first_name": "PEGGY", "last_name": "WANG", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-03-01", "end_date": "2030-12-31", "award_amount": 406250, "principal_investigator": { "id": 44412, "first_name": "Brielin", "last_name": "Brown", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 3417, "ror": "", "name": "UNIVERSITY OF PENNSYLVANIA", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "Most human diseases are complex, manifesting from an interplay between genes and environment over the lifespan that involve myriad biological processes. Genome-wide association studies have primarily implicated non-coding variation that is thought to lead to disease via disruption of complex, multi-level biological systems. Thus, improvements in our understanding of these fundamental processes underlying disease necessitates studying the relationship between multiple omics (multi-omic) modalities, both longitudinally and in conjunction with non-omic data. While recent years have seen an explosion of studies collecting multi-omic data in human populations, analysis of these data remains challenging both statistically and computationally. Here, I propose several new methods based on correlated latent factor models that will extend the capabilities of multi-omic inference methods to more complex study designs. I will develop model-based imputation methods that allow robust handling of missing data, enabling larger-scale studies of multi-omic biological contexts, and allowing researchers to design targeted multi-omic panels to extract the maximum amount of clinically-relevant information. I will develop multi-omic analysis methods that integrate across tissues and time points, enabling the study of dynamic molecular process and detection of systems-level impacts of intervention or disease onset. Finally, I will develop integration methods based on non-linear representation learning. This will enable detection of complex relationships between omics methods and integration with structured non-omics data such as doctor’s notes and radiographic images. To demonstrate the broad utility of the proposed methods, I will conduct collaborative analyses of varied cohorts. These include a population of individuals with subclinical atherosclerosis (MESA), a study anlyzing the relationship between microbiome features and immune health in the context of the COVID-19 pandemic (ImmunoMicrobiome), and a study of the impact of Alzheimer’s disease on neuroimaging and spinal uid biomarkers (ADNI). Completion of this research program will provide new insights into the fundamental biological processes underlying a host of common conditions, while bootstrapping the larger multi-omics research community by providing new tools that can handle complex study designs and integration tasks.", "keywords": [ "Alzheimer's Disease", "Atherosclerosis", "Biological", "Biological Markers", "Biological Process", "COVID-19 pandemic", "Communities", "Complex", "Computing Methodologies", "Data", "Data Analyses", "Detection", "Disease", "Environment", "Etiology", "Explosion", "Genes", "Human", "Image", "Individual", "Intervention", "Learning", "Machine Learning", "Methods", "Modality", "Modeling", "Multiomic Data", "Onset of illness", "Population", "Process", "Research", "Research Design", "Research Personnel", "Spinal", "Structure", "Time", "Tissues", "Untranslated RNA", "Variant", "biological systems", "clinically relevant", "cohort", "data imputation", "design", "detection platform", "genome wide association study", "human disease", "immune health", "improved", "insight", "life span", "microbiome", "molecular dynamics", "multimodality", "multiple omics", "neuroimaging", "novel", "programs", "radiological imaging", "statistics", "tool" ], "approved": true } }, { "type": "Grant", "id": "15961", "attributes": { "award_id": "1R35GM161641-01", "title": "Methods for quantifying selection and predicting evolutionary dynamics", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 44409, "first_name": "RONALD", "last_name": "ADKINS", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-03-01", "end_date": "2030-12-31", "award_amount": 417620, "principal_investigator": { "id": 44410, "first_name": "John P", "last_name": "Barton", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 3416, "ror": "", "name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "Natural selection is central to many challenges in biology and medicine, from the emergence of drug resistance in pathogens to cancer evolution. Understanding selection can also aid in protein engineering and help identify clinically relevant mutations in human disease genes. Temporal genetic data — sequences and phenotypes sampled over time — can be an especially powerful tool for understanding selection because it allows us to observe evolutionary dynamics directly. But while temporal data from sources like pathogen surveillance, ancient DNA, and experimental evolution have grown tremendously in recent years, statistical analyses of these data remain challenging. My lab will continue to pioneer the development of new computational methods to learn from temporal genetic data, revealing variants and phenotypes under selection and harnessing this information for predictive models of evolution. Over the past five years, we have developed several approaches to quantify selection from temporal data. Thanks to the use of mathematical methods from statistical physics, our methods are fast and accurate despite the inclusion of complex features such as linkage disequilibrium, epistasis, and time-varying selection. We demonstrated the power of these approaches through studies of HIV-1 immune escape and SARS-CoV-2 adaptation during the COVID-19 pandemic, where our analysis identified key mutations affecting viral transmission even before their importance was validated experimentally. Building on this foundation, we will pursue three synergistic research directions: First, we will develop new methods to jointly analyze selection on both individual mutations and phenotypic traits, fusing concepts from population genetics, quantitative genetics, and machine learning. Second, we will apply these methods to study rapid evolution in viral pathogens. Phenotypic models will help us to understand how immune pressure drives antigenic change in respiratory viruses and to compare evolutionary constraints on pathogens across host species. As an ambitious new direction, we will leverage these insights to develop predictive models of pathogen evolution, with influenza as a first target. Our research will systematically identify the features with the greatest power to predict evolution and characterize how and why predictive power may decline over time. Finally, we will extend our approaches to improve the interpretation of high-throughput mutagenesis experiments that measure the effects of thousands of mutations simultaneously. The proposed research will transform our understanding of how selection guides evolution across biological scales, from individual mutations to complex phenotypes, with applications ranging from predicting viral evolution to protein engineering. These advances could ultimately improve our ability to anticipate and control evolutionary processes across a wide range of biological contexts.", "keywords": [ "2019-nCoV", "Affect", "Biological", "Biology", "COVID-19 pandemic", "Complex", "Computing Methodologies", "DNA", "Data", "Data Sources", "Development", "Drug resistance", "Evolution", "Foundations", "Genes", "Genetic", "Genetic Epistasis", "Genotype", "HIV-1", "Immune", "Immunity", "Individual", "Influenza", "Learning", "Linkage Disequilibrium", "Machine Learning", "Malignant Neoplasms", "Maps", "Measures", "Medicine", "Methods", "Modeling", "Mutagenesis", "Mutation", "Natural Selections", "Phenotype", "Physics", "Play", "Population Genetics", "Process", "Protein Engineering", "Public Health", "Quantitative Genetics", "Research", "Resistance development", "Role", "Sampling", "Shapes", "Statistical Data Interpretation", "Statistical Methods", "Time", "Variant", "Viral", "clinically relevant", "experimental study", "genetic variant", "human disease", "improved", "insight", "mathematical methods", "pathogen", "pathogenic virus", "predictive modeling", "pressure", "respiratory virus", "tool", "trait", "viral transmission" ], "approved": true } }, { "type": "Grant", "id": "15960", "attributes": { "award_id": "2R25NS117281-06", "title": "Training in Advanced Statistical Methods in Neuroimaging and Genetics", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Neurological Disorders and Stroke (NINDS)" ], "program_reference_codes": [], "program_officials": [ { "id": 44407, "first_name": "LETITIA ALEXIS", "last_name": "WEIGAND", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-04-01", "end_date": "2031-03-31", "award_amount": 261311, "principal_investigator": { "id": 44408, "first_name": "ROBERT C.", "last_name": "WELSH", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 3415, "ror": "", "name": "UNIVERSITY OF CALIFORNIA LOS ANGELES", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "This education project is a continuation of our current, national class, Training in Advanced Statistical Methods in Neuroimaging and Genetics. Over the past 15 year the National Institutes of Health has greatly increased funding of grants that utilized advanced neuroimaging methods, genetic methods, and advanced statistical methods. While introductory courses are offered, ours is the only advanced course offered in the United States that provides an intensive, hands-on (“doing”) learning opportunity to better prepare biomedical and clinical researchers in advanced statistical methods. In one decade the combined budgets that utilize these advanced analysis techniques from the National Institute of Neurological Disorders and Stroke, National Institute of Mental Health, National Institute on Aging, National Institute on Drug Abuse, and National Institute of Biomedical Imaging and Bioengineering grew 5-fold, and there continues to be a great need to provide an educational opportunity to ensure the workforce is well positioned to carry out important work that has been identified by these and other institutes. Our program will continue to meet this need. We bring together a group of diverse world-class scientists and educators in a two-week intensive format to provide theoretical lectures paired with hands-on computer tutorials. Our course has served 103 students (55 total in 2021-2022 via Zoom due to COVID-19), and in 2023 (our 1st year of in-person) we taught 20 students, and 28 students in 2024 (in-person). We will enroll 26-30 students in April 2025 session. In our competitive renewal we will continue to enroll 26-30 students per year. With this being an advanced course, we ensure that the students accepted are a good education-level match for the content. We also implement mechanisms to maximize diverse perspective in our students and our teaching faculty. These students are accepted from across the United States, with attention to attracting a diverse student cohort. This education program will continue to distribute Tuition Awards based on financial need. We have evolved our course based on feedback from our current course alumni. In our class, over two weeks, students learn and put into practice methods such as: hierarchical statistical models, Bayesian statistics, network science, functional and structural connectomics, disease driven degeneration of the brain, and methods for analysis of genetics data such as polygenic risk scoring and structural equation modeling. The course concludes with lectures and labs on multi-modal analysis (imaging and imaging-genetics), and classification methods for biomarker development. Our course now includes 5 guest lecturers and team building activities outside of the classroom. To ensure students apply the acquired knowledge and skills to their independent research projects back at their home institutes, we supplement the course with our innovative continuing education: zoom-based sessions with the faculty for 8-months post formal course and students having near-real-time access regarding technical implementation questions through the Slack. This continued education portion greatly increases success utilizing their new practical skills in their own research.", "keywords": [ "Address", "Attention", "Award", "Back", "Bayesian Analysis", "Behavioral Research", "Biomedical Research", "Brain", "Budgets", "COVID-19", "Classification", "Clinical", "Clinical Research", "Communities", "Computers", "Continuing Education", "Course Content", "Data", "Disease", "Education", "Education Projects", "Educational Curriculum", "Educational Status", "Educational process of instructing", "Effectiveness", "Electronic Mail", "Enrollment", "Ensure", "Equation", "Evolution", "Faculty", "Feedback", "Funding", "Genetic", "Grant", "Home", "Image", "Institution", "Instruction", "Internet", "Knowledge", "Knowledge acquisition", "Learning", "Link", "Manuscripts", "Measures", "Methods", "Mission", "Modeling", "Monitor", "National Institute of Biomedical Imaging and Bioengineering", "National Institute of Drug Abuse", "National Institute of Mental Health", "National Institute of Neurological Disorders and Stroke", "National Institute on Aging", "Output", "Persons", "Positioning Attribute", "Postdoctoral Fellow", "Preparation", "Productivity", "Publishing Peer Reviews", "Qualifying", "Reporting", "Reproducibility", "Research", "Research Ethics", "Research Personnel", "Research Project Grants", "Resources", "Scholarship", "Science", "Scientist", "Secure", "Statistical Data Interpretation", "Statistical Methods", "Statistical Models", "Structure", "Students", "Study Section", "Techniques", "Time", "Training", "United States", "United States National Institutes of Health", "Universities", "Utah", "Work", "YouTube", "biomarker development", "career", "cohort", "data mining", "educational atmosphere", "equity diversity and inclusion", "follow-up", "genetic analysis", "graduate student", "imaging genetics", "implementation questions", "innovation", "instructor", "lecturer", "lectures", "meetings", "multimodal data", "multimodality", "neuroimaging", "polygenic risk score", "predictive modeling", "programs", "response", "skills", "success", "symposium", "undergraduate student" ], "approved": true } }, { "type": "Grant", "id": "15957", "attributes": { "award_id": "1R01AI196011-01", "title": "Protective mRNA Vaccines Against Tuberculosis", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 44404, "first_name": "KATRIN", "last_name": "EICHELBERG", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-04-06", "end_date": "2031-03-31", "award_amount": 717003, "principal_investigator": { "id": 27480, "first_name": "ADEL M", "last_name": "TALAAT", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 799, "ror": "", "name": "UNIVERSITY OF WISCONSIN-MADISON", "address": "", "city": "", "state": "WI", "zip": "", "country": "United States", "approved": true }, "abstract": "Protective mRNA Vaccines Against Tuberculosis. Summary. Tuberculosis (TB), caused by Mycobacterium tuberculosis (M. tb), remains a significant global health challenge, affecting approximately one-third of the world’s population and resulting in nearly 1.4 million deaths annually. The existing vaccine, M. bovis BCG (BCG), offers variable protection, with efficacy ranging from 0% to 80%. Our previous research has identified several innovative platform technologies aimed at enhancing vaccine development for major infections impacting both human and animal health. Notably, we have developed unique nano-adjuvant systems (NAS) that have demonstrated effectiveness against respiratory infections, including coronavirus and M. avium. In this project, we will utilize our expertise in tuberculosis vaccine development and nanoparticle vaccine platforms to assess the protective efficacy of a novel combination vaccine against TB. Our approach incorporates cutting-edge mRNA vaccine technology delivered via QuilA-DOTAP (QTAP), a novel lipid nanoparticle delivery adjuvant that ensures stable mRNA transcript delivery at various temperatures suitable for use in TB- endemic regions. Preliminary analyses of QTAP-adjuvanted combination mRNA vaccine encoding three mycobacterial antigens (Ag85B, Hsp70, and EsxH), referred to as QRNA, have shown robust protective immunity in mouse models challenged with both low and high doses of the virulent M. tb Erdman strain. In this project, we plan to First; examine the safety and immunogenicity of QRNA vaccines in variable murine models using both immune-compromised (Rag1-/-) and immune-competent (C3HeB/FeJ) murine models. Second; analyze the protective role of QRNA vaccine as a homologous or heterologous vaccine primed with BCG against challenge with M. tb Erdman (lineage 4, laboratory strain) or HN878 (lineage 2, hypervirulent clinical strain). Finally, we will assess protective immunity of QRNA vaccines in guinea pigs to identify vaccine-induced immune correlates of protection elicited by the mRNA vaccine candidates in guinea pigs, a TB model that mimic human infection. Once achieved, results from those aims will enhance our understanding of RNA-based immunization against TB. Future projects will further dissect the generated immunity in non-human primates, a more relevant model for human TB.", "keywords": [ "Address", "Adjuvant", "Adopted", "Adult", "Aerosols", "Affect", "Animals", "Antigens", "Area", "BCG Vaccine", "Bacille Calmette-Guerin vaccination", "C3HeB/FeJ Mouse", "CD8B1 gene", "Categories", "Cavia", "Cells", "Cessation of life", "Clinical", "Combined Vaccines", "Coronavirus", "Developing Countries", "Development", "Disease", "Disease Outbreaks", "Dose", "Effectiveness", "Emerging infection", "Ensure", "Flow Cytometry", "Future", "Generations", "Health", "Human", "IL17 gene", "Immune", "Immune response", "Immunity", "Immunization", "Immunocompetent", "Infection", "Interferon Type II", "Interleukin-2", "Laboratories", "Maps", "Messenger RNA", "Modeling", "Mus", "Mycobacterium Infections", "Mycobacterium avium", "Mycobacterium bovis", "Mycobacterium tuberculosis", "Outcome", "Outcomes Research", "Pathology", "Population", "Public Health", "RNA", "RNA vaccination", "RNA vaccine", "Rag1 Mouse", "Regimen", "Research", "Respiratory Tract Infections", "Rodent Model", "Role", "Safety", "System", "T-Lymphocyte", "TNF gene", "Technology", "Temperature", "Tissues", "Transcript", "Tuberculosis", "Tuberculosis Vaccines", "United States National Institutes of Health", "Vaccination", "Vaccines", "Virulent", "authority", "cytokine", "global health", "immunogenicity", "improved", "innovation", "lipid nanoparticle", "mRNA Stability", "mouse model", "mycobacterial", "nano", "nanoparticle", "nanoparticle delivery", "nonhuman primate", "novel", "protective efficacy", "technology platform", "transcriptome sequencing", "transcriptomic profiling", "tuberculosis immunity", "vaccine candidate", "vaccine development", "vaccine formulation", "vaccine immunogenicity", "vaccine platform", "vaccine safety" ], "approved": true } }, { "type": "Grant", "id": "15956", "attributes": { "award_id": "1R01AI189721-01A1", "title": "Decoding cellular networks governing respiratory mucosal IgA immunity", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 44403, "first_name": "HARIHARAN", "last_name": "SUBRAMANIAN", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-04-01", "end_date": "2031-03-31", "award_amount": 773388, "principal_investigator": { "id": 20818, "first_name": "Jie", "last_name": "Sun", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1426, "ror": "", "name": "MAYO CLINIC ROCHESTER", "address": "", "city": "", "state": "MN", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 3413, "ror": "", "name": "UNIVERSITY OF VIRGINIA", "address": "", "city": "", "state": "VA", "zip": "", "country": "United States", "approved": true }, "abstract": "Abstract/summary The factors and mechanisms driving robust respiratory mucosal immunity, particularly respiratory IgA responses, post-infection or vaccination are largely unknown. This represents a significant gap in our understanding necessary for designing future vaccination strategies aimed at providing enhanced mucosal protection against respiratory viral infections including new SARS-CoV-2 variants. This RO1 grant proposal aims to address this critical knowledge gap. Our central hypothesis is that the generation of mucosal IgA and respiratory protective immunity is contingent upon the localized interactions among pulmonary macrophages, CD4 T cells, and B cells within the respiratory tract. Three specific aims (SA) are proposed. Aim 1: Identify the associated mechanisms by which respiratory CD4+ T cells promote IgA production in situ. Aim 2: Elucidate TGFβ-dependent macrophages and B cell interactions in mucosal IgA production. Aim 3: Define the molecular and functional signatures of mucosal cross-reactive IgA-producing B cells. We believe that the insights obtained will be crucial in developing next-generation mucosal vaccines designed to effectively counter SARS-CoV-2 variants and other respiratory pathogens, significantly enhancing public health prevention strategies against respiratory infections. .", "keywords": [ "2019-nCoV", "Address", "Adenoviruses", "Alveolar Macrophages", "Animals", "Antibodies", "Applications Grants", "Area", "Automobile Driving", "B-Lymphocytes", "B-cell receptor repertoire sequencing", "Blood", "CD4 Positive T Lymphocytes", "Cell Communication", "Circulation", "Clinical Research", "Cloning", "Exhibits", "Future", "Generations", "Goals", "Hybrids", "Immune Evasion", "Immune response", "Immunity", "Immunoglobulin A", "Immunoglobulin G", "Immunologics", "In Situ", "Individual", "Infection", "Inhalation", "Intramuscular", "Knowledge", "Link", "Macrophage", "Maintenance", "Molecular", "Morbidity", "Mucosal Immunity", "Mucous Membrane", "Plasma Cells", "Prevention strategy", "Production", "Public Health", "RNA vaccination", "RNA vaccine", "Research", "Respiratory Mucosa", "Respiratory System", "Respiratory Tract Infections", "Role", "SARS-CoV-2 exposure", "SARS-CoV-2 infection", "SARS-CoV-2 variant", "Sea", "Secondary Immunization", "Severity of illness", "Shapes", "Signal Transduction", "Testing", "Th1 Cells", "Transforming Growth Factor beta", "Vaccinated", "Vaccination", "Vaccine Design", "Viral Respiratory Tract Infection", "Virus", "booster vaccine", "cross reactivity", "design", "dimer", "influenzavirus", "insight", "interleukin-21", "mortality", "mucosal vaccination", "mucosal vaccine", "next generation", "novel vaccines", "pathogenic virus", "pulmonary", "recruit", "respiratory", "respiratory pathogen", "response", "single-cell RNA sequencing", "transmission process", "vaccination strategy", "variants of concern", "viral transmission" ], "approved": true } }, { "type": "Grant", "id": "15954", "attributes": { "award_id": "1R01AG092810-01A1", "title": "The Impact of Changes in Primary Care Clinicians' Work Effort on the Health of Older Adults", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 44399, "first_name": "MARCEL", "last_name": "SALIVE", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-04-01", "end_date": "2031-01-31", "award_amount": 680086, "principal_investigator": { "id": 44400, "first_name": "Bruce E.", "last_name": "Landon", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 44401, "first_name": "Lisa", "last_name": "Rotenstein", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 2635, "ror": "", "name": "UNIVERSITY OF CALIFORNIA, SAN FRANCISCO", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "There are demonstrated benefits of comprehensive, continuous, and coordinated primary care for older adults, ranging from higher rates of appropriate preventive care receipt to lower rates of hospitalization and mortality. However, the benefits of strong primary care are threatened by an impending primary care workforce crisis, exacerbated by prevalent trends of primary care physician (PCP) workforce attrition and clinical effort reduction. Partly in response to these trends, there is increasing representation of NPs and PAs, collectively referred to as advanced practice clinicians (APCs), in the primary care workforce. However, burnout, intent to leave, and intent to reduce clinical effort are also prevalent among primary care APCs. These trends across primary care clinicians (PCCs; comprising physicians, NPs, and PAs) may significantly threaten quality of and access to care for older adults. At present, there is limited evidence to inform healthcare leaders and policy makers about how primary care workforce disruptions impact access to and quality of primary care received by older adults. There is additionally insufficient information on the actionable factors associated with PCC turnover and PCC reductions in clinical effort. In this grant, we will leverage data from Medicare fee-for-service and Medicare Advantage, which together provide coverage for 93% of older adults, in order to: 1) quantify the number of Medicare patients impacted by PCC turnover and sustained reductions in billed clinical effort and identify factors associated with these work effort changes; 2) assess the impact of PCC turnover and PCCs’ sustained reductions in billed clinical effort on patterns of primary care receipt and non-primary care utilization, including emergency department visits and hospitalizations; and 3) assess the impact of PCC turnover and sustained reductions in billed clinical effort on quality of care for older adults. All analyses will be conducted for the overall population of older adults as well as for subgroups of more vulnerable older adults, including those with dementia, multiple chronic conditions, and from underserved groups (e.g., dually eligible for Medicaid). Additionally, analyses will be conducted for physicians and APCs separately, and for the overall study period and comparing the pre- and post-COVID periods. The results from this study will elucidate how changes in PCCs’ work patterns influence the care of the growing US population of older adults. They will provide actionable insights for leaders seeking to design clinical systems and policies that enhance primary care for older adults. Overall, this proposal will enhance the ability of clinical, operational, and policy leaders to maintain the effort of the primary care workforce and optimize care for older adults.", "keywords": [ "Accident and Emergency department", "Address", "Affect", "COVID-19 pandemic", "Caring", "Clinical", "Complex", "Continuity of Patient Care", "Counseling", "Data", "Dementia", "Documentation", "Educational process of instructing", "Emergency department visit", "Fee-for-Service Plans", "Grant", "Health", "Health Care", "Health Services Accessibility", "Hospitalization", "Investments", "Left", "Location", "Measures", "Medicaid eligibility", "Medical Students", "Medicare", "Modeling", "Occupations", "Older Population", "Outcome", "Patients", "Pattern", "Physicians", "Policies", "Policy Maker", "Preventive care", "Primary Care", "Primary Care Physician", "Process", "Quality of Care", "Reporting", "Specialist", "Subgroup", "System", "Testing", "Time", "Underserved Population", "United States", "Visit", "Work", "acute care", "beneficiary", "burnout", "care delivery", "care providers", "care systems", "care utilization", "cost", "demographics", "design", "dual eligible", "hospitalization rates", "improved outcome", "insight", "large scale data", "mortality", "multiple chronic conditions", "older adult", "post-COVID-19", "primary care clinician", "response", "screening", "social", "trend" ], "approved": true } }, { "type": "Grant", "id": "15951", "attributes": { "award_id": "1K99HL183741-01", "title": "Modeling the Effect of Apolipoprotein LI Risk Variants on CVD Risk in African American E-cigarette Users Using Human Induced Pluripotent Stem-Cell-Derived Endothelial Cells", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 44395, "first_name": "KAREN MARY", "last_name": "NEILSON", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-04-01", "end_date": "2028-03-31", "award_amount": 127168, "principal_investigator": { "id": 44396, "first_name": "Jelena", "last_name": "Mustra Rakic", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2635, "ror": "", "name": "UNIVERSITY OF CALIFORNIA, SAN FRANCISCO", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "African American individuals face a disproportionately higher risk of tobacco-related cardiovascular diseases (CVD) than other races, a disparity not fully explained by traditional and socioeconomic risk factors. Despite lacking approval from the U.S. Food and Drug Administration (FDA) for their safety, e-cigarettes (e-cigs) have become increasingly popular, particularly among youth, and are now among the most commonly used tobacco products alongside traditional cigarettes. Approximately half of African American individuals carry at least one of two genetic variants (G1 and G2) of the apolipoprotein L1 (APOL1) gene, which are exceedingly rare in other populations. APOL1 is widely expressed, particularly in the vasculature. We have shown that carriers of APOL1 G1 and G2 variants have increased susceptibility to tobacco-related CVD, including stroke and coronary heart disease. Dysfunction of vascular endothelial cells (ECs) is a critical precursor to CVD. EC dysfunction also plays a key role in APOL1-associated pathology, including exacerbated renal issues and increased susceptibility to sepsis and severe COVID-19. Recent research indicates that, similar to cigarettes, both e-cigs and menthol—a flavor popular in the African American community—independently impair endothelial function. While studies, including those using induced pluripotent stem cell (iPSC)-derived ECs, demonstrate these effects, the specific impact of APOL1 risk variants on vascular health in African American tobacco product users remains unknown. The goal of the proposed research is to determine the effects of e-cigs, with and without menthol, on endothelial health, compare them to the effects of cigarettes, and identify potential molecular markers and pathways associated with CVD in African American users, with a focus on the APOL1 genotype. As such, this application aims to expand my background and expertise in modeling the CVD risk from tobacco products and to provide specific training in tobacco product-related in vitro assays, iPSC methodology, gene editing, and computational techniques. Building on my prior work in human studies, this research extends to the cellular level to address significant gaps in knowledge regarding the adverse effects of the most popular tobacco products, with and without menthol, among the African American population—a demographic long targeted by the tobacco industry marketing. To achieve this goal, I will use a robust in vitro platform of human iPSC-ECs to address the following aims: Aim K1) to determine the effect of e-cigs and cigarettes on markers of EC dysfunction in G1/G1 iPSC-ECs, Aim R1) to determine the effect of e-cigs and cigarettes on endothelial function in G2/G2 iPSC-ECs, and Aim R2) to determine the effect of e-cigs and cigarettes on inflammatory markers and lipid mediators of inflammation in G1/G1 and G2/G2 iPSC-ECs. This project will deepen our understanding of the adverse effects of widely used tobacco products on vascular health in the CVD-burdened African American population. It also aims to identify molecular markers of cardiovascular injury in this high-risk group, providing insights into the mechanisms of tobacco-related cardiovascular damage and supporting the development of targeted interventions.", "keywords": [ "Address", "Adverse effects", "African American", "African American population", "Aftercare", "Apolipoproteins", "Blood Vessels", "CCL2 gene", "CRISPR/Cas technology", "CXCL10 gene", "CXCR3 gene", "Cardiovascular Diseases", "Cardiovascular Models", "Cardiovascular system", "Cell Culture Techniques", "Cell Line", "Cell Physiology", "Cigarette", "Communities", "Computational Technique", "Coronary heart disease", "Development", "Disease", "Disease Management", "Disparity", "Electronic cigarette", "Endothelial Cells", "Endothelium", "Exhibits", "Exposure to", "Face", "Functional disorder", "Genes", "Genetic Markers", "Genotype", "Goals", "Health", "Human", "Impairment", "In Vitro", "Inflammation Mediators", "Inflammatory", "Interferon Type II", "Interleukin-1 beta", "Interleukin-6", "Intervention", "Ischemic Stroke", "Kidney", "Kidney Diseases", "Knowledge", "Link", "Marketing", "Menthol", "Mentors", "Modeling", "Molecular", "Molecular Target", "Pathology", "Pathway interactions", "Pattern", "Phase", "Phenotype", "Play", "Polyunsaturated Fatty Acids", "Population", "Predisposition", "Race", "Recording of previous events", "Research", "Risk", "Risk Factors", "Role", "Safety", "Sepsis", "Signal Transduction", "Smoker", "Smoking", "Stroke", "Study models", "TNF gene", "Tobacco", "Tobacco Industry", "Tobacco use", "Training", "United States Food and Drug Administration", "Variant", "Vascular Endothelial Cell", "Work", "Youth", "burden of illness", "cardiovascular disorder risk", "cardiovascular health", "cardiovascular injury", "cardiovascular risk factor", "cell injury", "cigarette smoking", "cigarette user", "clinically relevant", "combustible cigarette", "electronic cigarette use", "electronic cigarette user", "endothelial dysfunction", "genetic variant", "genome editing", "health disparity", "high risk", "high risk population", "human induced pluripotent stem cells", "improved", "in vitro Assay", "in vivo", "induced pluripotent stem cell", "inflammatory marker", "insight", "interest", "lipid mediator", "marginalized community", "molecular marker", "racial population", "risk variant", "severe COVID-19", "socioeconomics", "stem cell based approach", "tobacco products", "transcriptomics", "trend", "vaping", "vascular endothelial dysfunction", "vascular injury" ], "approved": true } }, { "type": "Grant", "id": "15949", "attributes": { "award_id": "1UG3NS143075-01A1", "title": "miR-10b Gene Editing Therapy for Glioblastoma", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Neurological Disorders and Stroke (NINDS)" ], "program_reference_codes": [], "program_officials": [ { "id": 44392, "first_name": "KELLY WILL", "last_name": "SHEPPARD", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-04-01", "end_date": "2028-03-31", "award_amount": 790474, "principal_investigator": { "id": 44393, "first_name": "Anna M.", "last_name": "Krichevsky", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 3408, "ror": "", "name": "BRIGHAM AND WOMEN'S HOSPITAL", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "Malignant glioma, particularly glioblastoma (GBM), remains among the most lethal forms of cancer and represents a significant unmet need in current medicine. The median survival of GBM patients is approximately 15-20 months with highly aggressive standard care, and the five-year survival rate is about 5%. There are no effective therapies for the disease. Over the years, we accumulated evidence that GBM growth and invasiveness are closely regulated by microRNAs, small regulatory molecules that control gene expression and strongly contribute to gliomagenesis. We demonstrated that this class of molecules holds great promise as therapeutic targets for neuro-oncology. Our work led us to focus on miR-10b, a unique growth and invasion-promoting miRNA and common molecular target for GBM in adults (otherwise a highly heterogeneous class of brain malignancies). We identified miR-10b, essential for glioma growth, as a top and common therapeutic target for GBM. Inhibition of miR-10b using different strategies reduced tumor growth in all tested glioma cell and animal models. CRISPR/Cas9 gene-editing of miR-10b emerged as the most potent therapeutic strategy in mice, and it holds great promise for GBM patients. We developed potent and safe lipid nanoparticle (LNP) -based miR-10b editing formulation as a new class of precision medicine for GBM. Our objective is to advance this miR-10b editing drug (called miRTED) into a “first-in-human” clinical trial in subjects with GBM. The Specific Aims of this project are, in UG3 component (Discovery phase): 1) Finalize the efficacy of miRTED administration using diverse orthotopic GBM models, 2) Assess the toxicity and off-target effects of miRTED administration using human and rodent neuroglial cells, brain organoids, and mouse models to establish dosing guidelines, and during UH3 component (Development phase): 3) Partner with BPN team and selected contract research organization to manufacture preclinical and then GMP-grade clinical lots of the LNP, 4) Partner with BPN team and selected contract research organization to conduct IND-enabling mouse toxicology and biodistribution studies, and 5) Finalize the writing and filing of the IND application with the FDA. Due to glioma “addiction” to miR-10b, the new strategy is expected to be highly efficacious for most, if not all, GBM patients despite the heterogeneity of the disease. This approach is principally different from other gene therapies proposed for the GBM- that all target only a subpopulation of patients. It can be used in combination with, or ultimately replace, the current standard care. In addition, the LNP formulations developed in this project could provide a platform technology for precision medicine targeting other tumor vulnerabilities. Notably, the recent success of COVID mRNA vaccines and in vivo gene editing trials provide POCs for the efficacy, safety, and scalability of mRNA/LNPs and CRISPR/Cas9 components in humans.", "keywords": [ "Adult", "Allografting", "Angiogenesis Inhibitors", "Animal Model", "Animals", "Antisense Oligonucleotide Therapy", "Antisense Oligonucleotides", "Apoptosis", "BCL2L11 gene", "Biodistribution", "Brain", "Brain Neoplasms", "CDKN1A gene", "CDKN2A gene", "COVID-19", "CRISPR/Cas technology", "Cell Cycle", "Cell Differentiation process", "Cell model", "Cells", "Clinical Pathways", "Clinical Trials", "Cytoprotection", "Development", "Diagnosis", "Disease", "Dose", "Drug Formulations", "EGFRvIII Peptide", "Epidermal Growth Factor Receptor", "Excision", "Exhibits", "FDA approved", "FDA-approved drug", "Formulation", "Gene Expression", "Genes", "Gliadel", "Glioblastoma", "Glioma", "Gliomagenesis", "Growth", "Guidelines", "Human", "Immunocompetent", "Immunotherapy", "Invaded", "Investigational New Drug Application", "Lead", "Malignant Glioma", "Malignant Neoplasms", "Mediating", "Medicine", "Messenger RNA", "MicroRNAs", "Modeling", "Molecular Target", "Mus", "Mutation", "Neuroglia", "Neurons", "Newly Diagnosed", "Organoids", "Patients", "Peptide Vaccines", "Pharmaceutical Preparations", "Phase", "Play", "RNA Splicing", "RNA delivery", "RNA vaccine", "Recurrence", "Regimen", "Research Contracts", "Resistance", "Rodent", "Role", "Safety", "Schedule", "Signal Pathway", "Survival Rate", "System", "Testing", "Therapeutic", "Toxic effect", "Toxicology", "Transcriptional Activation", "Tumor Cell Nuclei", "Tumor Subtype", "U6 small nuclear RNA", "Work", "Writing", "Xenograft procedure", "addiction", "bevacizumab", "checkpoint inhibition", "chemoradiation", "chemotherapy", "clinical lot", "disease heterogeneity", "drug development", "effective therapy", "first-in-human", "gene therapy", "in vivo", "inhibitor", "lipid nanoparticle", "manufacture", "mouse model", "mutational status", "nerve stem cell", "neuro-oncology", "neurosurgery", "oligonucleotide therapeutics", "patient subsets", "pharmacokinetics and pharmacodynamics", "pre-clinical", "precision medicine", "pro-apoptotic protein", "standard care", "standard of care", "success", "symptomatic improvement", "targeted therapy trials", "targeted treatment", "technology platform", "temozolomide", "therapeutic genome editing", "therapeutic target", "tumor", "tumor growth", "uncontrolled cell growth", "uptake" ], "approved": true } }, { "type": "Grant", "id": "15943", "attributes": { "award_id": "1R13OD039737-01", "title": "Annual Symposium on Nonhuman Primates", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 44387, "first_name": "SIGE", "last_name": "ZOU", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-05-01", "end_date": "2028-04-30", "award_amount": 74999, "principal_investigator": { "id": 8251, "first_name": "Deborah H.", "last_name": "Fuller", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 44388, "first_name": "Jon E", "last_name": "Levine", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 44389, "first_name": "Corinna Nicole", "last_name": "Ross", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 799, "ror": "", "name": "UNIVERSITY OF WISCONSIN-MADISON", "address": "", "city": "", "state": "WI", "zip": "", "country": "United States", "approved": true }, "abstract": "With this R13 application, we request funding to support, in part, the costs for planning, publicizing, and hosting the 42nd, 43rd, and 44th Annual Symposia on Nonhuman Primate Models for AIDS. For more than four decades, this symposium has served as the premier scientific forum for the exchange of information, including new research findings and scientific perspectives, among HIV/AIDS investigators whose research includes studies in nonhuman primates (NHPs). Disseminating the latest research findings in NHP models of AIDS while also facilitating discussion and exchange of information between basic scientists and clinicians remains a priority, as do focusing on emerging technologies to accelerate translation of NHP studies into the clinic and engaging a broader and more diverse group of researchers in HIV/AIDS research in NHP models. This meeting, the only one of its kind in the world, convenes an international group of scientists whose research focuses on the study of natural and experimental immunodeficiency virus infections in NHPs, as well as on the development of novel therapeutics, prophylactic vaccines for HIV, and curative approaches. Emerging topics in related infectious diseases (such as COVID-19 pathogenesis, vaccines and treatment) may also be included. The seven National Primate Research Centers (NPRCs) host this meeting in rotation, and upcoming symposia hosts will be the Wisconsin (2025), Southwest (2026), and Washington (2027) NPRCs. We plan a hybrid format with most participants attending in person and others joining online to access oral and poster sessions. The conference will begin on day 1 with registration, a keynote address by a leading HIV/AIDS researcher, and an evening reception. The following two and a half days will include scientific presentations from invited speakers and accepted oral abstracts. Each symposium scientific committee will select session topics and speakers to highlight new and cutting-edge technologies in their respective fields. Each session will open with a 30-minute talk by an invited chair. Individuals whose abstracts are accepted for oral presentations will give the remaining session talks. A poster session will occur on the evening of day 2, and there will be a banquet on the evening of day 3. As is traditional for this symposium, the Journal of Medical Primatology will publish all poster and oral abstracts in a special issue. In partnership with the HIV Vaccine Trials Network (HVTN), the NHP AIDS Symposium will also host a pre-symposium meeting for early-stage investigators (ESI). This meeting will be open to the attendees of a linked ESI Conference the HVTN sponsors. ESI attendees and mentors will focus on grant writing, budgeting, and networking, and will participate in a Q&A with NIH Program Officers. We believe bringing together researchers from a variety of diverse backgrounds will generate future collaborations and scientific advances. Knowledge shared and gained at upcoming Annual Nonhuman Primate Models for AIDS Symposia will further the continued, effective use of NHP models to maintain long term control of HIV replication in the absence of antiretroviral therapy and to design interventions to prevent or eradicate HIV infection.", "keywords": [ "2019-nCoV", "AIDS Vaccines", "Acceleration", "Acquired Immunodeficiency Syndrome", "Address", "Applications Grants", "Budgets", "COVID-19 pathogenesis", "COVID-19 treatment", "COVID-19 vaccine", "Clinic", "Collaborations", "Communicable Diseases", "Development", "Disease", "Drug Delivery Systems", "Emerging Technologies", "Epidemic", "Fees", "Fostering", "Funding", "Future", "Generations", "Grant", "HIV", "HIV Infections", "HIV Vaccine Trials Network", "HIV vaccine", "HIV/AIDS", "Health", "Human", "Hybrids", "Immune response", "Immunologist", "Individual", "International", "Intervention", "Journals", "Knowledge", "Life", "Link", "Logistics", "Medical", "Mentors", "Mission", "Monkeypox", "Oral", "Participant", "Pathogenesis", "Persons", "Preventive vaccine", "Primates", "Publishing", "Research", "Research Personnel", "Resources", "Rotation", "SIV", "Scientific Advances and Accomplishments", "Scientist", "Technology", "Testing", "Translations", "United States National Institutes of Health", "Universities", "Viral reservoir", "Virus", "Virus Diseases", "Washington", "Wisconsin", "Writing", "Zika Virus", "Zoonoses", "antiretroviral therapy", "cost", "disability", "emerging virus", "experience", "falls", "global health", "immunodeficiency", "innovation", "meetings", "neutralizing antibody", "nonhuman primate", "nonhuman primate models", "novel therapeutics", "novel vaccines", "originality", "pandemic virus", "posters", "prevent", "programs", "response", "symposium", "therapy design", "tool" ], "approved": true } } ], "meta": { "pagination": { "page": 2, "pages": 1424, "count": 14236 } } }